The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn.,

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40

The Pharma Data

SEPTEMBER 15, 2020

“ Amgen addresses important scientific questions to advance care and improve the lives of patients with serious diseases, including oncology, inflammation and cardiometabolic diseases, among others,” said Flavius Martin , vice president of Oncology, Inflammation and Site Head at Amgen South San Francisco.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

Drug Target Review

JULY 5, 2024

Since brain organoids can be derived from either diseased or healthy patients, they can recapitulate human (patho)physiology making them a better choice compared to mammalian cell systems that often fail to recapitulate the human phenotype. A regenerative approach to the treatment of multiple sclerosis. link] Madhavan M, et al.

Drugs 64

Drugs Targeted Protein Degradation Disease FDA Approval 64

Elrig

MARCH 22, 2023

At the same time, the chemical biology field is unveiling new ways to interrogate and understand biology, aiding deeper disease understanding and revolutionizing drug discovery. These fields are moving at remarkable speed and have huge potential to transform treatments.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

SugarCone Biotech

OCTOBER 6, 2024

These are in development for neurodegenerative diseases. Cancer cell viability was reduced by 50% - 80% after 7 days treatment in vitro, however only limited in vivo data was shown in this paper. It follows that some bispecific antibodies have been developed to the use an anti-Trf arm to bring a second binder into the CNS.

Targeted Protein Degradation 67

Targeted Protein Degradation International Engineering Therapies 67

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 9 Others, like psymberin, have been used as ADC payloads, with a β-glucuronide linker to target CD-30-positive and CD-70-positive malignancies.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

LifeSciVC

FEBRUARY 5, 2025

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which we are seeing novel innovation is in the targeting of transcription factors.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67